Obesity
Conditions
Brief summary
In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagrilintide can reduce the decline in bone mass associated to weight loss. Participants will either get cagrilintide, semaglutide, CagriSema (cagrilintide combined with semaglutide), or placebo. Which treatment participants get is decided by chance. Semaglutide is already approved for the treatment of overweight and obesity and can be prescribed by doctors. Cagrilintide and CagriSema are new medications currently under development for weight management. The study will last for about 79 weeks.
Interventions
DRUGCagrilintide
Participants will receive once-weekly cagrilintide subcutaneously.
DRUGSemaglutide
Participants will receive once-weekly semaglutide subcutaneously.
Participants will receive once-weekly placebo matched to cagrilintide subcutaneously.
Participants will receive once-weekly placebo matched to semaglutide subcutaneously.
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Female. * Post-menopausal at screening (defined as minimum 12 months of amenorrhea, high levels of follicular stimulating hormone (FSH) 16 - 130 international units per liter (IU/L), and low levels of anti-müllerian hormone (AMH) and inhibin B). * Age 50-70 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) greater than or equal to \>= 30.0 kilograms per square meter (kg/m\^2).
Exclusion criteria
* Previous or current bone disease (e.g., osteoporosis, Paget's disease of bone, or bone cancer). * Presence of disease affecting bone metabolism (e.g., diabetes mellitus, hyperparathyroidism, hyper or hypothyroidism, chronic kidney disease, celiac disease, or inflammatory diseases (e.g., psoriatic arthritis or ankylosing spondylitis)). * Treatment with any medication affecting bone metabolism within 6 months prior to screening as judged by the investigator (e.g., anti-resorptive medication, anabolic medication, systemic hormone replacement therapy (HRT), or systemic corticosteroids).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relative change in volumetric bone mineral density (vBMD) of the total hip assessed by quantitative computed tomography (QCT) | From baseline to end of treatment (week 68) | Measured in percentage (%). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relative changes in vBMD of the lumbar 1 (L1) - L4 vertebrae assessed by QCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in vBMD of the radius assessed by QCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in vBMD of the L1 - L4 vertebrae assessed by QCT | From baseline to week 20 | Measured in %. |
| Relative changes in trabecular thickness assessed by PCCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - positron emission tomography (PET) | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in number and separation of the femoral neck assessed by PCCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in C-terminal telopeptide of type I collagen (CTX-1) and procollagen type 1 N-terminal propeptide (P1NP) | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in CTX-1 and P1NP | From baseline to week 20 | Measured in %. |
| Relative changes in cortical thickness and porosity assessed by photon-counting computed tomography (PCCT) | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in L1-L2 vertebrae assessed by PCCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative changes in radius assessed by PCCT | From baseline to end of treatment (week 68) | Measured in %. |
| Relative change in the Ki (bone turnover) of the femoral neck assessed by fluoride - PET | From baseline to week 20 | Measured in %. |
Countries
Denmark
Contacts
Primary ContactNovo Nordisk
Outcome results
None listed